Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $30.56.

KROS has been the subject of a number of recent analyst reports. Truist Financial reduced their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Bank of America lowered Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Wedbush reaffirmed a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Scotiabank reduced their target price on Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating for the company in a report on Monday, May 12th. Finally, HC Wainwright reduced their target price on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, May 8th.

Keros Therapeutics Stock Performance

Shares of KROS opened at $13.33 on Friday. The firm has a market cap of $541.46 million, a P/E ratio of -74.06 and a beta of 1.26. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The business has a 50-day moving average of $14.00 and a 200 day moving average of $12.85.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same quarter in the previous year, the firm earned ($1.21) EPS. As a group, research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company’s stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider owned 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of large investors have recently modified their holdings of KROS. Bank of New York Mellon Corp boosted its position in shares of Keros Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company’s stock valued at $1,549,000 after acquiring an additional 2,462 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Keros Therapeutics by 7.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company’s stock valued at $4,427,000 after acquiring an additional 19,562 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Keros Therapeutics in the 4th quarter worth approximately $461,000. Finally, Swiss National Bank lifted its position in Keros Therapeutics by 4.8% in the 4th quarter. Swiss National Bank now owns 59,000 shares of the company’s stock worth $934,000 after buying an additional 2,700 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.